Advice
Marketing Authorisation Withdrawn
On 26 April 2019, the marketing authorisation for olaratumab (Lartruvo) was withdrawn.
Medicine details
- Medicine name:
- olaratumab (Lartruvo)
- SMC ID:
- 1273/17
- Indication:
- In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.
- Pharmaceutical company
- Eli Lilly and Company Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 13 November 2017